University of Wisconsin
School of Medicine and Public Health

Dudley Lamming, PhD

ASSISTANT PROFESSOR

ENDOCRINOLOGY, DIABETES & METABOLISM Faculty

VETERANS ADMINISTRATION HOSP
2500 OVERLOOK TER
MADISON, WI 53705-2254

(608) 256-1901 x12861

LAMMING LAB WEBSITE

Education

  • Harvard University – PhD, Experimental Pathology
  • Whitehead Institute for Biomedical Research, Cambridge, Massachusetts – Postdoctoral Fellow/Senior Research Associate

Professional Activities

Dr. Dudley Lamming is a faculty member of the Division of Endocrinology, Diabetes and Metabolism within the Department of Medicine. He is a fellow of the American Aging Association and the Gerontological Society of America; a recipient of the Gerontological Society of America Nathan Shock New Investigator Award and the American Physiological Society (Endocrinology and Metabolism Section) New Investigator Award; and an editorial board member of several peer-reviewed scientific journals.

Research Interests

View Dr. Dudley Lamming’s publications on NCBI My Bibliography

Dr. Lamming’s research focuses on understanding how nutrient-responsive signaling pathways can be harnessed to promote health and longevity. One major focus of his research is the regulation of metabolic health and aging by diet. His laboratory discovered that low protein diets promote metabolic health—improving blood sugar control and reducing adiposity—in humans and mice, and has identified dietary branched-chain amino acids (BCAA) as key regulators of these effects. His team currently studies the mechanisms that mediate these beneficial effects in mice and humans, with the goal of identifying interventions to treat and prevent diabetes and obesity. A second major focus of his laboratory is studying how reducing consumption of BCAAs may promote longevity and fitness, with an emphasis on understanding the role of the mechanistic Target of Rapamycin (mTOR), an amino acid- and insulin-responsive protein kinase, in this response. A third focus of the laboratory is understanding the biology of mTOR Complex 2 (mTORC2), which is a key effector of PI3K/insulin signaling. Finally, the laboratory is studying the ability of geroprotective interventions to treat or prevent Alzheimer’s disease using mouse models. 

Dr. Lamming's research has been supported by the National Institutes of Health/National Institute on Aging, the U.S. Department of Veterans Affairs, the American Federation for Aging Research (AFAR), the Glenn Foundation for Medical Research, the Wisconsin Partnership Program, the Progeria Research Foundation, and the American Diabetes Association.